We are live on ! Find out more
RCP

Rho Capital Partners Portfolio holdings

AUM $20.4M
This Fund
S&P 500
This Quarter Est. Return
+85.71%
1 Year Est. Return
–
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$154M
AUM Growth
+$55.1M
Cap. Flow
-$6.04M
Cap. Flow %
-3.91%
Top 10 Hldgs %
100%
Holding
5
New
–
Increased
–
Reduced
1
Closed
–

Top Buys

No buys this quarter

Top Sells

Rank Stock Value
1
TVRD
Tvardi Therapeutics
TVRD
+$6.04M

Sector Composition

Rank Sector Weight
1 Healthcare 91.27%
2 Communication Services 8.73%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
NGM
1
DELISTED
NGM Biopharmaceuticals, Inc. Common Stock
NGM
$74.4M 48.16%
3,766,666
– –
TVRD
2
Tvardi Therapeutics
TVRD
$23.5M
$47.9M 31%
77,752
-10,944
-12% -$6.04M
MRSN
3
DELISTED
Mersana Therapeutics
MRSN
$18.6M 12.07%
31,858
– –
LVO icon
4
LiveOne
LVO
$66M
$13.5M 8.73%
372,414
– –
SENS icon
5
Senseonics Holdings Inc
SENS
$254M
$62K 0.04%
7,980
– –

Similar funds

LUGPI
Lightspeed Ultimate General Partner IX Menlo Park, California $20.3M AUM 4.78% 1-Year Est. Return
IVM
InterWest Venture Management San Francisco, California $20.6M AUM 48.5% 1-Year Est. Return
SIC
Starr International Company Zug, Switzerland $19.9M AUM 39.69% 1-Year Est. Return
DOS
David O. Sacks $19.8M AUM 4.02% 1-Year Est. Return
AA
Antipodean Advisors New York $19.5M AUM 6.21% 1-Year Est. Return
CVSCT
C.V. Starr & Co Trust New York $19.4M AUM 28.57% 1-Year Est. Return
VNB
Virginia National Bank Charlottesville, Virginia $21.9M AUM 12.04% 1-Year Est. Return
BEP
Brookside Equity Partners Stamford, Connecticut $22.5M AUM 62.43% 1-Year Est. Return

Rho Capital Partners's Q2 2020 Portfolio in Review

As of Q2 2020, Rho Capital Partners held 5 positions worth $154M, up 56% from $99.3M the previous quarter. Its ten largest holdings account for 100% of the portfolio.

Rho Capital Partners withdrew a net $6.04M in Q2 2020, reducing 1 holding. Its largest reduction was Tvardi Therapeutics, cutting an estimated $6.04M.

By sector, the portfolio is most concentrated in Healthcare at 91% of assets, down from 94% a quarter earlier, followed by Communication Services.

  • Rho Capital Partners's biggest Q2 2020 reduction was Tvardi Therapeutics, cutting an estimated $6.04M.
  • Rho Capital Partners's ten largest holdings make up 100% of its $154M portfolio in Q2 2020.
  • Rho Capital Partners opened 0 new positions and closed 0 in Q2 2020.
  • Rho Capital Partners's portfolio value rose 56% quarter-over-quarter to $154M.

Based on Rho Capital Partners's 13F filing for Q2 2020, filed 7 Aug 2020.